Page last updated: 2024-12-11
13,14-dihydroretinoic acid
Description
## 13,14-Dihydroretinoic Acid (13,14-DHRA)
13,14-Dihydroretinoic acid (13,14-DHRA) is a **metabolite of retinoic acid (RA)**, a crucial vitamin A derivative involved in various biological processes.
**Here's what makes it significant for research:**
* **Unique Biological Activity:** Unlike RA, 13,14-DHRA is not a classical retinoid receptor agonist. It exhibits distinct biological effects, independent of the retinoic acid receptor (RAR) and retinoid X receptor (RXR) pathways.
* **Potential Therapeutic Applications:** 13,14-DHRA has shown promise in various areas, including:
* **Cancer Treatment:** Studies suggest it may possess anti-cancer properties by inhibiting tumor cell growth and angiogenesis (formation of new blood vessels).
* **Cardiovascular Health:** It has been linked to potential benefits in heart health, possibly by influencing lipid metabolism and reducing inflammation.
* **Skin Health:** Research indicates its role in regulating skin cell differentiation and promoting wound healing.
* **Neurological Disorders:** Preliminary studies suggest it may have neuroprotective effects, potentially relevant for conditions like Alzheimer's disease.
* **Metabolic Regulation:** 13,14-DHRA has been implicated in regulating energy metabolism and influencing lipid profiles, potentially impacting obesity and related health conditions.
* **Insights into Retinoid Metabolism:** Studying 13,14-DHRA helps researchers understand the complex metabolic pathways of vitamin A and how these processes affect various biological functions.
**Challenges and Future Directions:**
* **Limited Knowledge:** Although promising, research on 13,14-DHRA is still relatively limited. Further investigations are needed to fully understand its mechanisms of action, optimal therapeutic doses, and potential side effects.
* **Pharmacokinetic Studies:** Developing effective delivery methods and exploring the pharmacokinetic properties of 13,14-DHRA are crucial for its potential clinical applications.
In conclusion, 13,14-dihydroretinoic acid is a unique and potentially valuable metabolite of retinoic acid with distinct biological activities. Ongoing research into its therapeutic potential and intricate mechanisms of action holds promise for diverse medical applications and a deeper understanding of vitamin A metabolism.
13,14-dihydroretinoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 5326536 |
CHEBI ID | 194189 |
SCHEMBL ID | 4734748 |
MeSH ID | M0489529 |
Synonyms (7)
Synonym |
(4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-4,6,8-trienoic acid |
(4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-4,6,8-trienoic acid |
CHEBI:194189 |
13,14-dihydroretinoic acid |
all-trans-13,14-dihydroretinoic acid |
SCHEMBL4734748 |
9-cis-13,14-dihydro 13-methylretinoic acid |
Drug Classes (2)
Class | Description |
retinoid | Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof. |
monocarboxylic acid | An oxoacid containing a single carboxy group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.84 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.63 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |